- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
- Interventions
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
- Drug · Radiation · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 92
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
- Interventions
- Silmitasertib, Irinotecan, Temozolomide, Vincristine
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 19 more
- Conditions
- Melanoma
- Interventions
- Ipilimumab, Temozolomide, Cisplatin, Interferon Alfa-2b, Interleukin-2
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
- Interventions
- Chemotherapy with Temodar., Radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
- Interventions
- LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide), Immunotherapy (Pembrolizumab), Immunotherapy (nivolumab and relatlimab), Immunotherapy (ipilimumab and nivolumab)
- Biological · Drug
- Lead sponsor
- Linnaeus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- Newport Beach, California • San Francisco, California • Stanford, California + 6 more
- Conditions
- Childhood CNS Tumor
- Interventions
- SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
- Genetic · Radiation · Drug
- Lead sponsor
- SynerGene Therapeutics, Inc.
- Industry
- Eligibility
- 1 Year to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
- Interventions
- MN-166, Temozolomide
- Drug
- Lead sponsor
- MediciNova
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, temozolomide, temsirolimus, bevacizumab, sorafenib, surgery, radiation
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Childhood Solid Tumors
- Interventions
- Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Central Nervous System Tumor, Pediatric, Neuroblastoma
- Interventions
- temozolomide, thalidomide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma (GBM)
- Interventions
- Ketogenic Diet, Radiation therapy, Temozolomide
- Dietary Supplement · Radiation · Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- temozolomide, flow cytometry, staining method, biopsy, laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma, Skin Cancer
- Interventions
- Cisplatin, Vinblastine, Temozolomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 28 more
- Conditions
- Malignant Melanoma
- Interventions
- Decitabine, Temozolomide, biopsy
- Drug · Procedure
- Lead sponsor
- Hussein Tawbi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Melanoma
- Interventions
- Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ)
- Biological · Drug
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 21 more
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab with Chemotherapy
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERAS-801, ABBV-637, ABBV-155, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Indianapolis, Indiana + 8 more
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Interventions
- SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
- Device · Drug
- Lead sponsor
- CarThera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Brain Tumors
- Interventions
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Indoximod, Partial Radiation, Full-dose Radiation, Temozolomide, Cyclophosphamide, Etoposide, Lomustine
- Drug · Radiation
- Lead sponsor
- Theodore S. Johnson
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- Pembrolizumab, Methotrexate, Temozolomide, Rituximab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2018
- U.S. locations
- 92
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more